Jian Yang

Jian Yang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Surgery
Verified
Journal Article
Closed access
LKLingXiang Kong
LingXiang Kong
TLTao Lv
Tao Lv
LJLi Jiang
Li Jiang
JYJian Yang
Jian Yang
JYjiayin yang
jiayin yang
Although numerous scoring models are available to predict the prognosis of patients undergoing liver transplantation (LT), the field lacks a simple model for quick prediction of the short-term survival of patients after LT in the event that the donor's information is not available in advance. A total of 1495 adult patients underwent LT in the present study. Three-quarters of recipients were randomly selected into the test set (n = 1121), while the remaining 25% formed the validation set (n = 374). Univariate and multivariate analysis and machine-learning techniques were applied to evaluate possible influencing factors. To further simplify the model, a weighted-scoring system was designed considering each influencing factor and its importance in an artificial neural network (ANN). In the test set, multivariate analysis identified creatinine, age, and total bilirubin as independent risk factors, while albumin was an independent protective factor. Logistic regression analysis showed the C-statistic to be 0.650, while ANN indicated this to be 0.698. We simplified the model to obtain the final scoring model, for which the C-statistic was 0.636, and defined four risk grades. The 90-day mortality rates corresponding to the four risk levels were 6.2%, 11.8%, 24.0%, and 34.9%, respectively. In the validation set, the C-statistic value of the original model was 0.668 and that of the simplified model was 0.647. We developed a simple scoring system for the preliminary prediction of the postoperative 90-day mortality of adult LT based on preoperative characteristics of LT recipients.

26 May 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KHKun Huang
Kun Huang
PZPingwu Zhao
Pingwu Zhao
JZJiangying Zhao
Jiangying Zhao
PZPan Zhao
Pan Zhao
JYJian Yang
Jian Yang
Anaplastic lymphoma kinase (ALK)‑negative hepatic inflammatory myofibroblastic tumors (IMTs) harboring the ETS variant transcription factor 6‑neurotrophic receptor tyrosine kinase 3 (ETV6‑NTRK3) fusion gene and manifesting with biloma are extremely rare, and their biological behavior is unclear. The present study reports the case of a 45‑year‑old female with ALK‑negative IMT of the liver harboring the ETV6‑NTRK3 fusion gene and manifesting with biloma. Computed tomography of the abdomen confirmed the lesions to be a low‑density mass, measuring 11.2x8.5x10.5 cm, located in the left lobe of the liver, and a lower‑density mass, measuring 8.5x6.1x5.9 cm, located in the interior of the tumor. As the suspicion of a malignancy remained high, surgical resection of the left hepatic lobe, including the tumor, was undertaken. Intraoperatively, a tumor (12x10x9 cm), with an unclear boundary, incomplete capsule and fish‑like texture, was found in the left lateral lobe of the liver, and a biloma, measuring 8x6 cm, was identified inside the tumor. Pathological examination revealed spindle cell proliferation with infiltration of chronic inflammatory cells and mucinous degeneration. Immunohistochemical studies showed negativity for ALK, CD117, CD34, discovered on GIST‑1, desmin, smooth muscle actin, S‑100, CD21, pan‑cytokeratin, epithelial membrane antigen, CD23 and CD35, but positivity for vimentin staining, and 5% Ki‑67‑positive cells. Fluorescence in situ hybridization studies assessing characteristic genetic rearrangements using ALK, RET, ROS1, MDM2, MGEA5 and ETV6 break‑apart assays, revealed the presence of the ETV6‑NTRK3 fusion oncogene and negativity for ALK, RET, ROS1, MDM2 and MGEA5. The patient was discharged 7 days post‑operatively, without any adjuvant treatment. No recurrence of symptoms was noted at the 3‑year follow‑up. To the best of our knowledge, this is the first report of biloma in an ALK‑negative IMT of the liver, which may increase our understanding of hepatic IMT.

8 November 2022 in International Immunopharmacology
Verified
Journal Article
Open access
JYJingsheng Yuan
Jingsheng Yuan
ZLZijian Liu
Zijian Liu
ZWZhenru Wu
Zhenru Wu
JYJiayin Yang
Jiayin Yang
JYJian Yang
Jian Yang
Hepatocellular carcinoma (HCC) remains a global health challenge due to high recurrence and metastasis rates. The interferon regulatory factor (IRF) family plays an essential role in the tumour immune microenvironment. However, an IRF family-based score that can predict prognosis and response to immunotherapy in HCC patients has not been adequately investigated. Here, we comprehensively evaluated the expression landscape and prognostic significance of IRF family genes as well as their relationship with the immune microenvironment. We further screened IRF4-associated genes to construct a signature and explored their biological features. Then, we established an IRF4 risk score consisting of nine IRF4-associated genes. Importantly, we demonstrated significant differences in the prognostic stratification and immune characteristics of HCC patients with different IRF4 risk scores. The predictive capability of the IRF4 risk score was validated in different HCC subgroups and independent HCC cohorts. Moreover, immunohistochemical analysis of our HCC cohort revealed a positive correlation between IRF4 and PD-1 expression. In vitro experiments demonstrated that the overexpression of IRF4 inhibited the proliferation and migration capacity of HCC cells by restricting the JAK2/STAT3 signalling pathway and epithelial-mesenchymal transition. Overall, our study identified a novel IRF4 risk score that could serve as a robust prognostic biomarker and provide therapeutic benefits for immunotherapy in HCC patients, which may be helpful for clinical decision-making for HCC patients.

8 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CJChenhao Jiang
Chenhao Jiang
CCChuwen Chen
Chuwen Chen
YZYongjie Zhou
Yongjie Zhou
JYJian Yang
Jian Yang
JYJiayin Yang
Jiayin Yang
Paragangliomas are highly vascularised and often heritable tumors derived from the paraganglia. They are typically discovered in the retroperitoneal space as well as the head and neck region but are rarely encountered in the liver parenchyma. We report a case of a primary functioning hepatic paraganglioma and provide an up-to-date literature review of patients with such tumors. We present a case of functioning paraganglioma in a 34-year-old female patient who suffered a solitary lesion in her left lateral lobe with symptoms of hypertension since pregnancy. She did not have any family history and her pre-pregnancy examination was negative. An abdominal CT imaging revealed a 6.5 × 5.7 cm liver lesion in segments II and III. Laboratory investigations identified elevation in plasma-free catecholamines. With sufficient preoperative preparation, the patient underwent laparoscopic left hemihepatectomy. Immunohistochemical staining revealed Syn (+) tumor cell nests surrounded by S-100 sustentacular cells (+), providing a definitive diagnosis of paraganglioma. The patient recovered uneventfully without signs of recurrence during a 1-year follow-up period. Our case demonstrates that primary refractory hypertension in pregnancy should be screened for paraganglioma through abdominal ultrasound and plasma free catecholamines. On the other hand, laparoscopic surgery is technically safe and feasible for the treatment of patients with hepatic paragangliomas in favorable locations.